SOLV vs ICU vs BAX vs HOLX

For growth investors, Baxter International Inc.

(BAX) is the stronger pick with 5. 7% revenue growth year-over-year, versus 0. 9% for Solventum Corporation (SOLV). Solventum Corporation (SOLV) offers the better valuation at 8. 3x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Solventum Corporation (SOLV) is the cheapest at 8.

3x versus Hologic, Inc. at 30. 5x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 8%, compared to -98. 3% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus ICU's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus Baxter International Inc. 's 1. 38β — meaning BAX is approximately 205% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Baxter International Inc.

(BAX) is pulling ahead at 5. 7% versus 0. 9% for Solventum Corporation (SOLV). On earnings-per-share growth, the picture is similar: Solventum Corporation grew EPS 221. 7% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, BAX leads at 3. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Solventum Corporation (SOLV) is the more profitable company, earning 18.

7% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 18. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SOLV leads at 26. 2% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Baxter International Inc.

(BAX) trades at 9. 4x forward P/E versus 17. 2x for Hologic, Inc. — 7. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SOLV: 25. 6% to $92. 17.

In this comparison, BAX (3.

8% yield) pays a dividend. SOLV, ICU, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), +124. 3% 10Y return). Both have compounded well over 10 years (HOLX: +124. 3%, ICU: -98. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SOLV is a mid-cap deep-value stock; ICU is a small-cap quality compounder stock; BAX is a small-cap income-oriented stock; HOLX is a mid-cap quality compounder stock. BAX pays a dividend while SOLV, ICU, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.